Vincerx announces potential distribution of $0.04-$0.08 per share

SAN MATEO, Calif. - Vincerx Pharma, Inc. (OTC Pink:VINC) has updated shareholders regarding its upcoming Special Meeting to vote on the company’s dissolution and liquidation plan, estimating a potential distribution of $0.04 to $0.08 per share to stockholders if the proposal is approved. The announcement comes as the company’s stock has declined nearly 99% over the past year, according to InvestingPro data, with shares currently trading at $0.04.

The Special Meeting, previously adjourned, is now scheduled for July 16, 2025, at 10:00 a.m. Pacific time and will be held virtually.

The company emphasized that delays in approving the dissolution proposal would result in continued operating expenses that could reduce or eliminate funds available for distribution to shareholders. Vincerx’s board has unanimously recommended stockholders vote in favor of the dissolution.

According to the company, timely approval would preserve the possibility of distributions and potentially allow U.S. stockholders who receive less than their tax basis in shares to recognize a capital loss for federal income tax purposes.

"Every vote matters. Stockholders must actively vote for their vote to count," the company stated in its press release, noting that further delays would increase expenditures and reduce the likelihood and amounts available for distribution.

The dissolution proposal and additional information have been filed with the Securities and Exchange Commission. Vincerx has engaged Advantage Proxy as its proxy solicitor to assist shareholders with voting.

The estimated distribution range is based on current assumptions and is subject to change, according to the company’s statement.

In other recent news, Vincerx Pharma has announced significant developments impacting its operations and future. The company is set to be delisted from the Nasdaq Stock Market after failing to meet the minimum bid price requirement, with trading suspension scheduled for April 23, 2025. Vincerx has decided against appealing the delisting decision and will voluntarily deregister its common stock. Concurrently, the company has canceled its proposed merger with QumulusAI and is initiating a wind-down of its operations. The board has directed management to explore asset monetization and out-licensing opportunities as part of this process. Vincerx’s forward-looking statements highlight potential risks, such as the need for bankruptcy protection and the challenges of securing shareholder approval for the wind-down. The company’s recent filings with the SEC may provide further insights into these strategic shifts. Investors and stakeholders are advised to consider these developments when evaluating Vincerx Pharma’s current position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.